However, recent studies have revealed that LOXL3 is frequently overexpressed in multiple types of malignant tumors, and its expression level is closely correlated with advanced tumor stage, lymph node metastasis, and poor patient prognosis (Laurentino et al., 2019). Here, LOXL3 is linked to metastatic malignant neoplasm in the lymph nodes.